All In Biotech

Drug Trial Radar · NCT05978492

A Study of TXN10128 in Subjects With Solid Tumors

A Multicenter, Open-label, Phase 1 Dose Escalation and Expansion Study of TXN10128, an Inhibitor of ENPP1 as Monotherapy and Combination Therapy With Irinotecan or Paclitaxel in Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Jul 27, 2023

Primary completion

Dec 31, 2025

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Txinno Bioscience Inc.Industry
Sponsor type
Industry
First posted
Aug 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I clinical trial to primarily evaluate the safety, tolerability, and addtionally assess pharmacokinetics, pharmacodynamics, and antitumor activity of investigational product, TXN10128. The target subjects will be consisted of patients with locally advanced (unresectable) or metastatic soild tumors. This study includes a dose-escalation part and a dose-expansion part, and a TXN10128 monotherapy part and a TXN10128 + Irinotecan or Paclitaxel combination therapy part.

Conditions

  • Locally Advanced (Unresectable) or Metastatic Solid Tumors

Interventions

  • TXN10128Drug

    TXN10128: Oral administration once daily everyday

  • IrinotecanDrug

    Intravenous (IV) administration at 150 mg/m2 twice (Day 1 and Day 15) at intervals of 2 weeks in one cycle

  • PaclitaxelDrug

    IV administration at 80 mg/m2 three times (Day 1, Day 8, and Day 15) at intervals of 1 week in one cycle (IV administration at 90 mg/m2 for patients with breast cancer)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: Day 1 up to Day 21 for Cohort A(TXN10128 mono cohort) and Day 1 up to Day 28 for Cohort B,C(TXN10128 combination with Irinotecan or paclitaxel cohort) in dose escalation period
  2. Adverse events (AE)Time frame: Up to 30 days from end of treatment

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Gachon University Gil Medical Center

    Incheon, South Korea · Recruiting

  • SAMSUNG Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

  • Chungbuk National University Hospital

    Cheonju, North Chungcheong, South Korea · Recruiting

  • Seoul National Univ. Hospital

    Seoul, Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.